Small Cell Lung Cancer Extensive Stage
Oncology·MeSH: Small Cell Lung Carcinoma
Prevalence
6.0 / 100K
Incidence
8.0 / 100K/yr
9 drugs in development·5 companies·4 clinical trials
Drug Pipeline by Phase
Phase 3(4)
Phase 2(1)
| Drug | Company |
|---|---|
| Etoposide | Merck & Co., Inc. (MRK) |
Phase 1(3)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| Gocatamig | Merck & Co., Inc. (MRK) |
Compare drugs
Frequently asked questions
How many drugs are in development for Small Cell Lung Cancer Extensive Stage?
BioSniper tracks 9 drugs in development for Small Cell Lung Cancer Extensive Stage across 5 companies.
How many clinical trials target Small Cell Lung Cancer Extensive Stage?
There are 4 clinical trials targeting Small Cell Lung Cancer Extensive Stage tracked by BioSniper.
What is the prevalence of Small Cell Lung Cancer Extensive Stage?
The estimated prevalence of Small Cell Lung Cancer Extensive Stage is approximately 6.0 per 100,000 population.
Deep-dive into Small Cell Lung Cancer Extensive Stage
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis